Table 1.
Baseline characteristics and 2-year survival probabilities with 95% confidence intervals.
| Covariate | Category | Frequency n (%) | Deaths n (%)a | 2-Year Survival (95 CI%) | Log-rank test (p-value) |
|---|---|---|---|---|---|
| Overall | 2079 (100) | 367(22.67)/1619 (17.65) | 71 (66, 74) | ||
| Sex | Male | 1290 (62.14) | 215/998 (21.54) | 69 (63, 75) | 0.19 |
| Female | 786 (37.86) | 151/619 (24.39) | 72 (67, 77) | ||
| Age | 18–24 | 286 (13.89) | 45/232 (19.40) | 71 (56, 82) | <0.05 |
| 25–34 | 655 (31.81) | 120/495 (24.24) | 68 (60, 74) | ||
| 35–44 | 645 (31.33) | 133/492 (27.03) | 66 (58, 72) | ||
| > 45 | 473 (22.97) | 67/384 (17.45) | 79 (71, 86) | ||
| Year of diagnosis | 1996 – 2000 | 139 (6.69) | 20/104 (19.23) | 77 (61, 87) | 0.04 |
| 2001 | 359 (17.27) | 47/267 (17.60) | 78 (69, 84) | ||
| 2002 | 557 (26.79) | 102/453 (22.52) | 67 (56, 75) | ||
| 2003 | 546 (26.26) | 127/440 (28.86) | 68 (62, 73) | ||
| 2004 | 478 (22.99) | 71/355 (20.00) | 72 (60, 81) | ||
| TB/MDR-TB history | No | 145 (7.15) | 16/105 (15.24) | 85 (76, 91) | 0.12 |
| Yes | 1,8882 (92.85) | 348/1,479 (23.53) | 70 (65, 74) | ||
| HIV status | Negative | 859 (41.32) | 101/656 (15.40) | 76 (60, 82) | <0.05 |
| Positive | 554 (26.65) | 169/445 (37.98) | 54 (47, 61) | ||
| Status unknown | 666 (32.03) | 97/518 (26) | 79 (74, 83) | ||
| Ethambutol Resistance | Known | 1,444 (55.03) | 146/911 (16.03) | 78 (72, 82) | <0.05 |
| Unknown | 935 (44.97) | 221/708 (31.21) | 62 (56, 68) | ||
| Kanamycin Resistance | Known | 437 (20.97) | 62/382 (16.23) | 76 (68, 82) | <0.05 |
| Unknown | 1,643 (79.03) | 305/1,237 (24.66) | 69 (64, 73) | ||
| Ofloxacin/Ciprofloxacin Resistance | Known | 326 (15.68) | 57/286 (19.93) | 71 (62, 79) | 0.19 |
| Unknown | 1,753 (84.32) | 310/1,333 (23.26) | 71 (66, 75) |
a
Frequencies and percentages based on complete observed data, so the totals do not necessary equal those in the third column, which a gives a count of the subjects enrolled.